Literature DB >> 23743734

Prostate biopsy: results and advantages of the transperineal approach--twenty-year experience of a single center.

Pietro Pepe1, Francesco Aragona.   

Abstract

PURPOSE: Detection rate for prostate cancer (PCa) and complications following transperineal prostate biopsy (TPBx) were reported.
METHODS: From January 1991 to December 2012, 4,000 men underwent TPBx; from 1991 to 2001, the patients underwent biopsy for suspicious DRE or PSA values >4 ng/mL; moreover, from 2002, the indications were abnormal DRE, PSA >10 ng/mL, PSA values between 4.1 and 10, 2.6 and 4 and <2.5 ng/mL with F/T PSA <25, <20 <15 %, respectively. In case of initial biopsy, the number of needles cores increased from 6 (1991-1996) to 12 (1997-2012) and 18 cores (2002-2012); in case of repeat biopsy, since 2005 a saturation biopsy (SPBx) with >24 cores was performed.
RESULTS: Overall, PCa, normal parenchyma, HGPIN and ASAP were found in 1,379 (34.5 %), 2,400 (60 %), 175 (4.4 %) and 46 (1.1 %) patients, respectively; in case of initial TPBx, the scheme at 18 showed a greater PCa detection in comparison with scheme at 6-12 cores (p < 0.05). In case of repeat biopsy, a higher detection of microfocus of cancer was found performing a SPBx; moreover, 15 % of cancers were localized in the anterior zone. Incidence of hemospermia and urinary retention were correlated with the number of needle cores resulting equal to 30.4 versus 11.1 % in case of SPBx (p < 0.05); moreover, none developed sepsis.
CONCLUSIONS: Transperineal prostate biopsy (TPBx) resets the risk of sepsis; moreover, in case of repeat SPBx, the transperineal approach detects a high number of significant PCa localized in the anterior zone (15 % of the cases).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23743734     DOI: 10.1007/s00345-013-1108-1

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  27 in total

1.  International variation in prostate cancer incidence and mortality rates.

Authors:  Melissa M Center; Ahmedin Jemal; Joannie Lortet-Tieulent; Elizabeth Ward; Jacques Ferlay; Otis Brawley; Freddie Bray
Journal:  Eur Urol       Date:  2012-03-08       Impact factor: 20.096

2.  Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer.

Authors:  Winston E Barzell; Myron R Melamed; Paul Cathcart; Caroline M Moore; Hashim U Ahmed; Mark Emberton
Journal:  J Urol       Date:  2012-07-19       Impact factor: 7.450

3.  Estimates of cancer incidence and mortality in Europe in 2008.

Authors:  J Ferlay; D M Parkin; E Steliarova-Foucher
Journal:  Eur J Cancer       Date:  2010-01-29       Impact factor: 9.162

4.  The role of transperineal template prostate biopsies in restaging men with prostate cancer managed by active surveillance.

Authors:  Benjamin E Ayres; Bruce S I Montgomery; Neil J Barber; Nicola Pereira; Stephen E M Langley; Philippa Denham; Simon R J Bott
Journal:  BJU Int       Date:  2011-08-19       Impact factor: 5.588

5.  Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging.

Authors:  Peter A Pinto; Paul H Chung; Ardeshir R Rastinehad; Angelo A Baccala; Jochen Kruecker; Compton J Benjamin; Sheng Xu; Pingkun Yan; Samuel Kadoury; Celene Chua; Julia K Locklin; Baris Turkbey; Joanna H Shih; Stacey P Gates; Carey Buckner; Gennady Bratslavsky; W Marston Linehan; Neil D Glossop; Peter L Choyke; Bradford J Wood
Journal:  J Urol       Date:  2011-08-17       Impact factor: 7.450

6.  Incidence of insignificant prostate cancer using free/total PSA: results of a case-finding protocol on 14,453 patients.

Authors:  P Pepe; F Aragona
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-08-17       Impact factor: 5.554

7.  Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare.

Authors:  Stacy Loeb; H Ballentine Carter; Sonja I Berndt; Winnie Ricker; Edward M Schaeffer
Journal:  J Urol       Date:  2012-10-09       Impact factor: 7.450

8.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

9.  Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate.

Authors:  K K Hodge; J E McNeal; M K Terris; T A Stamey
Journal:  J Urol       Date:  1989-07       Impact factor: 7.450

10.  Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting.

Authors:  A V Taira; G S Merrick; R W Galbreath; H Andreini; W Taubenslag; R Curtis; W M Butler; E Adamovich; K E Wallner
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-09-29       Impact factor: 5.554

View more
  10 in total

1.  Transperineal template prostate biopsies in men with raised PSA despite two previous sets of negative TRUS-guided prostate biopsies.

Authors:  Shady Nafie; Raj P Pal; John P Dormer; Masood A Khan
Journal:  World J Urol       Date:  2013-12-14       Impact factor: 4.226

2.  Robotic Transrectal Ultrasound Guided Prostate Biopsy.

Authors:  Sunghwan Lim; Changhan Jun; Doyoung Chang; Doru Petrisor; Misop Han; Dan Stoianovici
Journal:  IEEE Trans Biomed Eng       Date:  2019-01-07       Impact factor: 4.538

3.  A new 5-grading score in the diagnosis of prostate cancer with real-time elastography.

Authors:  Guang Xu; Lijing Feng; Minghua Yao; Jian Wu; Lehang Guo; Xudong Yao; Lixia Zhao; Huixiong Xu; Rong Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  A randomized controlled comparison between periprostatic nerve block and pelvic plexus block at the base and apex of 14-core prostate biopsies.

Authors:  Sung Jin Kim; Jongpill Lee; Dong Hyeon An; Chang-Hoo Park; Ju Hyun Lim; Han Gwun Kim; Jong Yeon Park
Journal:  World J Urol       Date:  2019-03-12       Impact factor: 4.226

5.  Evaluation of robot-assisted MRI-guided prostate biopsy: needle path analysis during clinical trials.

Authors:  Pedro Moreira; Niravkumar Patel; Marek Wartenberg; Gang Li; Kemal Tuncali; Tamas Heffter; Everette C Burdette; Iulian Iordachita; Gregory S Fischer; Nobuhiko Hata; Clare M Tempany; Junichi Tokuda
Journal:  Phys Med Biol       Date:  2018-10-16       Impact factor: 3.609

6.  Positive Culture Prior to Transperineal Prostate Biopsy Was Not Associated with Post-Biopsy Febrile Urinary Tract Infection Development.

Authors:  Yoichiro Tohi; Kengo Fujiwara; Satoshi Harada; Iori Matsuda; Ayako Ito; Mari Yamasaki; Yasuyuki Miyauchi; Yuki Matsuoka; Takuma Kato; Rikiya Taoka; Hiroyuki Tsunemori; Nobufumi Ueda; Mikio Sugimoto
Journal:  Res Rep Urol       Date:  2021-09-07

Review 7.  Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis.

Authors:  Spyridon P Basourakos; Mark N Alshak; Patrick J Lewicki; Emily Cheng; Michael Tzeng; Antonio P DeRosa; Mathew J Allaway; Ashley E Ross; Edward M Schaeffer; Hiten D Patel; Jim C Hu; Michael A Gorin
Journal:  Eur Urol Open Sci       Date:  2022-01-29

8.  Impact of prostate biopsy technique on outcomes of the precision prostatectomy procedure.

Authors:  Ralph Grauer; Michael A Gorin; Akshay Sood; Mohit Butaney; Phil Olson; Guillaume Farah; Renee Hanna Cole; Wooju Jeong; Firas Abdollah; Mani Menon
Journal:  BMJ Surg Interv Health Technol       Date:  2022-07-06

Review 9.  Schema and cancer detection rates for transperineal prostate biopsy templates: a review.

Authors:  Abhinav Sidana; Fernando Blank; Hannah Wang; Nilesh Patil; Arvin K George; Hasan Abbas
Journal:  Ther Adv Urol       Date:  2022-06-26

10.  Comparisons of cancer detection rate and complications between transrectal and transperineal prostate biopsy approaches - a single center preliminary study.

Authors:  Guan-Lin Huang; Chih-Hsiung Kang; Wei-Ching Lee; Po-Hui Chiang
Journal:  BMC Urol       Date:  2019-10-28       Impact factor: 2.264

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.